Uncategorized

Sionna’s cystic fibrosis failure is a windfall for Vertex’s blockbuster franchise

Published

on

A surprise flop in Phase 2a cystic fibrosis trial sent Sionna’s shares plummeting, but for Vertex, the news reinforced its standard-of-care standing with highly successful drugs like Trikafta.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version